AGP Executive Report
Last update: 8 hours agoTrial Halted: A controversial U.S.-backed hepatitis B study in Guinea-Bissau will not proceed after the government refused approval. The plan would have delayed the birth dose for half of about 14,000 newborns until six weeks, drawing strong ethical concerns because the vaccine is proven to prevent infection. Vaccine Seizure: Judicial police searched the Bandim Health Project’s offices and seized vaccine doses during an investigation into the shipment. Police said the seizure does not establish any problem with the vaccines’ quality, safety or effectiveness. Guinea-Bissau plans to introduce a universal hepatitis B birth dose in 2028; health advocates say newborns should receive it sooner.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.